Enterprise Value to EBITDA Ratio: UroGen Pharma Ltd. (URGN)
The commercialization of oncology gels activates operating leverage for UroGen Pharma Ltd. (URGN), scaling profits as clinic coverage expands. The company's EV/EBITDA multiple clearly confirms this trend, with the current metric standing at 0.00. A unique bladder drug delivery system creates a patent barrier, while the development of a platform for various types of cancer minimizes the risks of clinical failures.
Metric breakdowns and analytics for UroGen Pharma Ltd (URGN)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
URGN - Company Net Income|Expected Profit UroGen Pharma Ltd.|URGN - Price to Earnings Multiple|Projected Price to Earnings UroGen Pharma|URGN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization UroGen Pharma|URGN - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) UroGen Pharma|URGN - Earnings per share for the trailing year|Quarterly EPS earnings growth urogen.com|URGN - Earnings growth in current year|Net earnings per share growth forecast for next year UroGen Pharma Ltd.
- company sales and revenue statistics:
Summary company analysis:URGN (UroGen Pharma Ltd)
The EV/EBITDA multiple compares the total enterprise value of UroGen Pharma Ltd. (URGN), including net debt, with its operating profit before taxes and amortization to determine the asset's real price. By analyzing changes in the EV/EBITDA level of UroGen Pharma Ltd. (URGN), an investor can identify stock overvaluation amid risks of slow adoption for bladder cancer treatments and potential pricing pressure from insurance companies.
Competitor analysis
BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Bicara Bio - Business Value to Operating Income Before Depreciation|PSNL (Personalis Inc) - EV/EBITDA Multiple|Company Value to EBITDA Erasca, Inc. ERAS|EV/EBITDA Multiple DCTH|YMAB - Company Value to EBITDA|Aura Biosciences Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Candel Therapeutics CADL|accuray.com - EV/EBITDA Multiple|SLS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU (actuatetherapeutics.com) - Enterprise Value to EBITDA Ratio|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tuhurabio.com|EV/EBITDA Multiple Protara Tx|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology (CSBR) - Company Value to EBITDA|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple
